NASDAQ:RNAZ | Free Cash Flow | Transcode Therapeutics, Inc.

Free cash flow is operating cash flow less capital expenditure. FCF / net income requires positive matching-period earnings.

Available history
2020-12-31 to 2026-03-31
Data captured

Historical Free Cash Flow

DateOperating cash flowCapital expenditureFree cash flowFCF / net income
2026-03-31-$4.98M
2025-12-31-$8.14M
2025-03-31-$3.1M
2024-12-31-$3.15M$500.00-$3.15M
2024-03-31-$3.94M$3,836.00-$3.94M
2023-12-31-$5.66M$0.00-$5.66M
2023-03-31-$4.51M$12,896.00-$4.53M
2022-12-31-$4.02M$28,215.00-$4.05M
2022-03-31-$3.95M$30,657.00-$3.98M
2021-12-31-$1.6M$85,728.00-$1.69M
2021-03-31-$522,153.00$75,301.00-$597,454.00
2020-12-31-$255,491.00

Annual Free Cash Flow

DateOperating cash flowCapital expenditureFree cash flowFCF / net income
2025-12-31-$19.52M$6,660.00-$19.52M
2024-12-31-$13.34M$21,761.00-$13.36M
2023-12-31-$18.07M$35,609.00-$18.11M
2022-12-31-$15.76M$100,919.00-$15.86M
2021-12-31-$5.27M$254,820.00-$5.52M
2020-12-31-$492,971.00